Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults.
APOE
Alzheimer’s disease (AD)
magnetic resonance imaging (MRI)
polygenic risk score (PRS)
white matter hyperintensities
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2024
2024
Historique:
received:
05
12
2023
revised:
25
06
2024
accepted:
12
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
Reduced brain volumes and more prominent white matter hyperintensities on MRI scans are commonly observed among older adults without cognitive impairment. However, it remains unclear whether rates of change in these measures among cognitively normal adults differ as a function of genetic risk for late-onset Alzheimer's disease, including
Identifiants
pubmed: 39229494
doi: 10.1093/braincomms/fcae276
pii: fcae276
pmc: PMC11369827
doi:
Types de publication
Journal Article
Langues
eng
Pagination
fcae276Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.
Déclaration de conflit d'intérêts
The following authors declare that they have no competing interests: A.S., J.W., C.P., C.D., G.E., T.J.H., L.D., M.B., S.M.R., L.A.R.-R., R.L., T.B., J.C.M. and J.F. C.L.M. and M.S.A. are advisors to Eli Lilly. S.C.J. has served as an advisor to Roche Diagnostics. S.M.L. is a scientific advisor to Cytox Ltd.